UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size Enlarge Text
Click to increase the text size.
Restore Text
Click to restore original text size.
Reduce Text
Click to decrease the text size.
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
Text Sizer image
Home About and More Information Transporter Data Index

In following the US Food and Drug Administration-led Critical Path Initiative, the FDA has partnered with the Giacomini lab at UCSF to create a transporter database of pharmacologically relevant transporters to support development of new pharmaceuticals. Information on important transporters, their localization, expression levels, substrates, and inhibitors have been curated from the literature and compiled into a single location to aid and inform drug developers, regulatory agencies and academic scientists about transporters important in drug action and disposition.. The database will also help drug developers in determining what experiments or analyses must be conducted to check for possible drug interactions through transporters as well as identify promising transporter candidates for the testing of possible genetic influences.

Critical Path Initiative Information:
The Critical Path Initiative (CPI) is FDA's national strategy for transforming the way FDA-regulated products--human drugs, biological products, medical devices, and veterinary drugs--are developed, evaluated, and manufactured. FDA launched the Critical Path Initiative (CPI) in 2004 to tackle the steep decline in the number of innovative medical products being submitted for approval—and getting to patients—despite the enormous breakthroughs being made in biomedical science. Creating safer, more effective treatments and ensuring that our nation remains safe and globally competitive are all part of FDA’s responsibility to fulfill its mission. One key CPI area of focus is supporting partnerships to accelerate the development of personalized medicine.

Giacomini Lab Information:
Dr. Kathleen Giacomini is a leader in the study of pharmacogenomics – how an individual’s genetics determine his or her response to medicines. The research in Dr. Giacomini's lab focuses on the roles of membrane transporters in drug absorption, disposition, targeting, and in clinical drug response. In particular, lab research is focused on pharmacogenomics of membrane transporters. A key aspect of the group's pharmacogenetic studies is to discover naturally occurring variants in transporter genes in ethnically diverse human populations that associate with variation in drug response.

This project is supported by funds from the Critical Paths Initiative of the FDA. This site is 508 compliant.

Home page graphics information:
transporter plus drugs yield unknown interactions

Graphical elements for the home page graphic were taken from a PowerPoint slide created by Dr. Avner Schlessinger of the Sali Lab here at UCSF. Dr. Schlessinger is involved in determining substrate specificity within and across SLC families using sequence- and structure-based approaches. The slide in question was created to demonstrate the process of predicting substrate specificity for the Norepinephrine transporter (NET). Not all elements of the original slide were used. The initial structural representations were generated with Pymol on a Mac.

Citing information:
If you use any information from this website, please cite the following publication:
Morrissey KM, Wen CC, Johns SJ, Zhang L, Huang SM, Giacomini KM, "The UCSF-FDA TransPortal: A Public Drug Transporter Database", Clinical Pharmacology and Therapeutics (2012) 92(5):545-6.

Helpful links

Contact us | Glossary

Blue banner